150 related articles for article (PubMed ID: 23864098)
1. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.
DeCensi A; Bonanni B; Maisonneuve P; Serrano D; Omodei U; Varricchio C; Cazzaniga M; Lazzeroni M; Rotmensz N; Santillo B; Sideri M; Cassano E; Belloni C; Muraca M; Segnan N; Masullo P; Costa A; Monti N; Vella A; Bisanti L; D'Aiuto G; Veronesi U;
Ann Oncol; 2013 Nov; 24(11):2753-60. PubMed ID: 23864098
[TBL] [Abstract][Full Text] [Related]
2. HRT opposed to low-dose tamoxifen (HOT study): rationale and design.
Decensi A; Galli A; Veronesi U
Recent Results Cancer Res; 2003; 163():104-11; discussion 264-6. PubMed ID: 12903847
[TBL] [Abstract][Full Text] [Related]
3. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
4. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.
Chang J; Powles TJ; Ashley SE; Gregory RK; Tidy VA; Treleaven JG; Singh R
Ann Oncol; 1996 Sep; 7(7):671-5. PubMed ID: 8905024
[TBL] [Abstract][Full Text] [Related]
5. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives.
Guerrieri-Gonzaga A; Galli A; Rotmensz N; Decensi A
Ann N Y Acad Sci; 2001 Dec; 949():113-22. PubMed ID: 11795343
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
7. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
Decensi A; Gandini S; Serrano D; Cazzaniga M; Pizzamiglio M; Maffini F; Pelosi G; Daldoss C; Omodei U; Johansson H; Macis D; Lazzeroni M; Penotti M; Sironi L; Moroni S; Bianco V; Rondanina G; Gjerde J; Guerrieri-Gonzaga A; Bonanni B
J Clin Oncol; 2007 Sep; 25(27):4201-9. PubMed ID: 17709798
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
9. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Aihara T; Takatsuka Y; Ohsumi S; Aogi K; Hozumi Y; Imoto S; Mukai H; Iwata H; Watanabe T; Shimizu C; Nakagami K; Tamura M; Ito T; Masuda N; Ogino N; Hisamatsu K; Mitsuyama S; Abe H; Tanaka S; Yamaguchi T; Ohashi Y
Breast Cancer Res Treat; 2010 Jun; 121(2):379-87. PubMed ID: 20390343
[TBL] [Abstract][Full Text] [Related]
11. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
Wang PH; Horng HC; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):127-34. PubMed ID: 17638620
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.
Salmon RJ; Ansquer Y; Asselain B; Languille O; Lesec G; Remvikos Y
Oncol Rep; 1999; 6(3):699-703. PubMed ID: 10203618
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and breast cancer: revisiting the issues.
DeGregorio MW; Taras TL
J Am Pharm Assoc (Wash); 1998; 38(6):738-44; quiz 744-6. PubMed ID: 9861792
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
17. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
18. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
